Sensei Biotherapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Sensei Biotherapeutics, Inc. | |||
| Date: | February 29, 2024 | By: | /s/ John Celebi |
|---|---|---|---|
| John Celebi | |||
| President and Chief Executive Officer | |||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ John Celebi | President, Chief Executive Officer and Director (Principal Executive Officer) | February 29, 2024 |
| John Celebi | ||
| /s/ Erin Colgan | Chief Financial Officer (Principal Financial and Accounting Officer) | February 29, 2024 |
| Erin Colgan | ||
| /s/ William Ringo | Chair | February 29, 2024 |
| William Ringo | ||
| /s/ Bob Holmen | Director | February 29, 2024 |
| Bob Holmen | ||
| /s/ James Peyer, Ph.D. | Director | February 29, 2024 |
| James Peyer, Ph.D. | ||
| /s/ Thomas Ricks | Director | February 29, 2024 |
| Thomas Ricks | ||
| /s/ Deneen Vojta, M.D. | Director | February 29, 2024 |
| Deneen Vojta, M.D. | ||
| /s/ Jessie English, Ph.D. | Director | February 29, 2024 |
| Jessie English, Ph.D. | ||
| /s/ Kristian Humer | Director | February 29, 2024 |
| Kristian Humer | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Common Stock and Stockholders’ Equity for the Years Ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.